Avestar Capital LLC Acquires 4,296 Shares of Gilead Sciences, Inc. $GILD

Avestar Capital LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 31.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 18,114 shares of the biopharmaceutical company’s stock after purchasing an additional 4,296 shares during the quarter. Avestar Capital LLC’s holdings in Gilead Sciences were worth $2,008,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in GILD. Norges Bank purchased a new stake in Gilead Sciences during the 2nd quarter valued at approximately $2,150,268,000. Price T Rowe Associates Inc. MD boosted its position in shares of Gilead Sciences by 314.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock worth $1,647,484,000 after acquiring an additional 11,156,382 shares during the last quarter. Nuveen LLC purchased a new position in Gilead Sciences during the first quarter valued at $620,415,000. Invesco Ltd. increased its holdings in Gilead Sciences by 33.5% in the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after acquiring an additional 3,394,330 shares during the last quarter. Finally, Kingstone Capital Partners Texas LLC purchased a new stake in Gilead Sciences in the 2nd quarter worth $238,083,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $126.54, for a total value of $1,265,400.00. Following the completion of the sale, the chief executive officer owned 571,203 shares of the company’s stock, valued at $72,280,027.62. This trade represents a 1.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $125.08, for a total value of $625,400.00. Following the transaction, the director owned 8,920 shares of the company’s stock, valued at $1,115,713.60. This trade represents a 35.92% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 135,757 shares of company stock worth $16,616,127. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $121.22 on Friday. The firm has a market capitalization of $150.40 billion, a price-to-earnings ratio of 18.79, a PEG ratio of 0.68 and a beta of 0.32. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The business has a 50 day simple moving average of $120.94 and a 200-day simple moving average of $115.25. Gilead Sciences, Inc. has a 1 year low of $88.57 and a 1 year high of $128.70.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.16 by $0.31. The firm had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio is currently 48.99%.

Wall Street Analysts Forecast Growth

GILD has been the subject of a number of research analyst reports. Truist Financial assumed coverage on Gilead Sciences in a research report on Monday, November 24th. They set a “buy” rating and a $140.00 price objective for the company. Scotiabank initiated coverage on Gilead Sciences in a report on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 price target for the company. The Goldman Sachs Group lifted their price objective on Gilead Sciences from $108.00 to $110.00 and gave the stock a “neutral” rating in a research note on Friday, October 31st. TD Cowen increased their target price on Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. Finally, Citigroup boosted their price target on shares of Gilead Sciences from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $130.65.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.